J&J Medical Connect
IMAAVY™

(nipocalimab-aahu)

This information is intended for US patients and caregivers to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended to promote the use of our products, nor to provide medical advice.

IMAAVY™ (nipocalimab-aahu)

Patient Medical Information

What Should I Tell My Healthcare Provider Before Starting IMAAVY?

Last Updated: 05/01/2025

summary

Here is a passage from the IMAAVY PATIENT INFORMATION which may be helpful to address your question:

Before receiving IMAAVY, tell your healthcare provider about all of your medical conditions, including if you:

  • ever had an allergic reaction to IMAAVY. Ask your healthcare provider if you are not sure.1 
  • have or have had any recent infections or have any symptoms of infection.1 
  • have recently received or are scheduled to receive an immunization (vaccine). People who are being treated with IMAAVY should not receive live vaccines.1 
  • are pregnant or plan to become pregnant. It is not known whether IMAAVY will harm your unborn baby.1 
    • Pregnancy Safety Study. There is a pregnancy safety study for IMAAVY if IMAAVY is given during pregnancy or you become pregnant while receiving IMAAVY. Your healthcare provider should report IMAAVY exposure by contacting Johnson and Johnson at 1-800-526-7736 or www.IMAAVY.com.
  • are breastfeeding or plan to breastfeed. IMAAVY can pass into your breast milk, and it is not known whether IMAAVY will harm your baby. Talk to your healthcare provider about the best way to feed your baby if you receive IMAAVY.1 

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.1 

ADDITIONAL INFORMATION

This information is provided ONLY in response to your request and is not intended as medical advice, to promote the use of our product, or suggest using it in any manner other than as described in the PRESCRIBING INFORMATION. All decisions regarding your medical treatment should be made with your healthcare professional(s). Please contact your healthcare professional(s) to discuss the information in this response.

Please refer to the attached full PRESCRIBING INFORMATION and the PATIENT INFORMATION for IMAAVY.1 

 

References

1 IMAAVY (nipocalimab-aahu) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc;https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/IMAAVY-pi.pdf